Literature DB >> 25410097

A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome.

Cheng-Che Shen1, Albert C Yang1, Jeng-Hsiu Hung1, Li-Yu Hu1, Shih-Jen Tsai2.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. We used a nationwide population-based retrospective cohort study to explore the relationship between PCOS and the subsequent development of gynecological cancers including uterine, breast, or ovarian cancer.
METHODS: We identified subjects who were diagnosed with PCOS between January 1, 2000, and December 31, 2004, in the Taiwan National Health Insurance (NHI) Research Database. A comparison cohort was constructed for patients without known PCOS who were also matched according to age. All PCOS and control patients were observed until diagnosed with breast cancer, ovarian cancer, or uterine cancer or until death, withdrawal from the NHI system, or December 31, 2009.
RESULTS: The PCOS cohort consisted of 3,566 patients, and the comparison cohort consisted of 14,264 matched control patients without PCOS. The adjusted hazard ratio (HR) of uterine cancer and breast cancer in subjects with PCOS were higher (HR: 8.42 [95% confidence interval: 1.62-43.89] and HR: 1.99 [95% confidence interval: 1.05-3.77], respectively) than that of the controls during the follow-up. With the Monte Carlo method, only the mean adjusted HR of 1,000 comparisons for developing uterine cancer during the follow-up period was greater for the PCOS group than for the control groups (HR: 4.71, 95% confidence interval: 1.57-14.11).
CONCLUSION: PCOS might increase the risk of subsequent newly diagnosed uterine cancer. It is critical that further large-scale, well-designed studies be conducted to confirm the association between PCOS and gynecological cancer risk. ©AlphaMed Press.

Entities:  

Keywords:  Breast cancer; Ovarian cancer; Polycystic ovary syndrome; Retrospective cohort study; Uterine cancer

Mesh:

Year:  2014        PMID: 25410097      PMCID: PMC4294614          DOI: 10.1634/theoncologist.2014-0311

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  24 in total

1.  Carcinoma of the endometrium in young women.

Authors:  H SPEERT
Journal:  Surg Gynecol Obstet       Date:  1949-03

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  Clinical/pathologic features and patient outcome in early onset endometrial carcinoma: a population based analysis and an institutional perspective from the Detroit metropolitan area, Michigan.

Authors:  Assaad Semaan; Rouba Ali-Fehmi; Adnan R Munkarah; Sudeshna Bandyopadhyay; Robert T Morris; Sara Rizk; Ismail Mert; Julie J Ruterbusch; Michele L Cote
Journal:  Gynecol Oncol       Date:  2011-11-01       Impact factor: 5.482

4.  Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women.

Authors:  I Konishi; M Koshiyama; M Mandai; H Kuroda; S Yamamoto; K Nanbu; T Komatsu; K Matsushita; C V Rao; T Mori
Journal:  Gynecol Oncol       Date:  1997-05       Impact factor: 5.482

5.  Epithelial ovarian cancer risk among women with polycystic ovary syndrome.

Authors:  J M Schildkraut; P J Schwingl; E Bastos; A Evanoff; C Hughes
Journal:  Obstet Gynecol       Date:  1996-10       Impact factor: 7.661

6.  Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome).

Authors:  Louise A Brinton; Kamran S Moghissi; Carolyn L Westhoff; Emmet J Lamb; Bert Scoccia
Journal:  Fertil Steril       Date:  2009-11-25       Impact factor: 7.329

7.  Metabolic and cardiovascular consequences of polycystic ovary syndrome.

Authors:  F Orio; L Vuolo; S Palomba; G Lombardi; A Colao
Journal:  Minerva Ginecol       Date:  2008-02

Review 8.  Polycystic ovary syndrome and endometrial carcinoma.

Authors:  Paul Hardiman; Ouma C Pillay; William Atiomo
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

Review 9.  Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.

Authors:  H Teede; A Deeks; L Moran
Journal:  BMC Med       Date:  2010-06-30       Impact factor: 8.775

Review 10.  Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  John A Barry; Mallika M Azizia; Paul J Hardiman
Journal:  Hum Reprod Update       Date:  2014-03-30       Impact factor: 15.610

View more
  26 in total

1.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

Review 2.  Cancer in Transgender People: Evidence and Methodological Considerations.

Authors:  Hayley Braun; Rebecca Nash; Vin Tangpricha; Janice Brockman; Kevin Ward; Michael Goodman
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

3.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

4.  Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome.

Authors:  Laura M L Carvalho; Cláudia N Ferreira; Daisy K D de Oliveira; Kathryna F Rodrigues; Rita C F Duarte; Márcia F A Teixeira; Luana B Xavier; Ana Lúcia Candido; Fernando M Reis; Ieda F O Silva; Fernanda M F Campos; Karina B Gomes
Journal:  J Assist Reprod Genet       Date:  2017-09-13       Impact factor: 3.412

5.  SNHG1 Long Noncoding RNA is Potentially Up-Regulated in Colorectal Adenocarcinoma.

Authors:  Niloofar Avazpour; Mohamadreza Hajjari; Seyed Reza Kazemi Nezhad; Maryam Tahmasebi Birgani
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01

6.  Authors' reply to: Anti-Müllerian hormone and breast cancer risk: is the correlation possibly associated with PCOS.

Authors:  Tess V Clendenen; Joanne Dorgan; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-10-26       Impact factor: 7.396

7.  Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.

Authors:  Holly R Harris; Kara L Cushing-Haugen; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Lorna Rodriguez; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Sara Lindström; Kathryn L Terry
Journal:  Int J Epidemiol       Date:  2019-06-01       Impact factor: 9.685

8.  The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.

Authors:  Reem A Al Khalifah; Iván D Flórez; Brittany Dennis; Binod Neupane; Lehana Thabane; Ereny Bassilious
Journal:  Syst Rev       Date:  2015-09-23

9.  Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.

Authors:  Cheng-Che Shen; Li-Yu Hu; Albert C Yang; Yung-Yen Chiang; Jeng-Hsiu Hung; Shih-Jen Tsai
Journal:  BMC Cancer       Date:  2016-11-03       Impact factor: 4.430

Review 10.  Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients.

Authors:  Dominik Rachoń
Journal:  Rev Endocr Metab Disord       Date:  2015-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.